Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
What is your protocol for intermittent ADT for prostate cancer?
Related Questions
Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?
How do you treat metastatic large cell neuroendocrine carcinoma of prostate with undetectable PSA, who had the treatment related transformation while on ADT monotherapy?
What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?
How often do you monitor for pancreatitis (check lipase/amylase) while on Axitinib?
If a patient diagnosed with seminoma after orchiectomy has margin positive disease noted in the spermatic cord and no overt metastasis on imaging and normal tumor markers, how should this patient be staged?
How would you sequence PARPi vs pembrolizumab for a patient who has progressed on ARPI to mCRPC that has somatic PALB2 mutation and MSI-H?
Are there any trials looking at alternative treatments for patients who otherwise would receive 2 years of ADT but have the HSD3B1 gene (homozygous vs heterozygous)?
Do you need renal biopsy before SBRT for RCC suspicious cancer?
Would you use olaparib after progression on an ARPI for a patient with somatic PALB2 mutated mCRPC?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
